Eric Winer, MD, discusses considerations for inavolisib plus palbociclib with fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.
Eric Winer, MD
Advertisement
Eric Winer, MD, is the director of Yale Cancer Center, as well as president and physician-in-chief at Smilow Cancer Hospital.
Articles by Eric Winer, MD
Advertisement
Latest Updated Articles
Dr Winer on Considerations for Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast CancerPublished: February 4th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5